2025 FDA TIDES (Peptides and Oligonucleotides) Harvest
Pharmaceuticals · 30.01.2026 · 19 (2) · 244
DOI: 10.3390/ph19020244 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmaceuticals, online erschienen am 30.01.2026. Verfasst von Danah AlShaer und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemical Engineering, Imperial College London, London SW7 2AZ, UK. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation (NRF) South Africa.
Abstract (Originalsprache)
In 2025, the FDA approved 46 novel drugs, including four TIDEs (one peptide, three oligonucleotides, and one antibody drug conjugate containing peptide as a payload). The three approved oligonucleotide therapeutics—fitusiran, donidalorsen, and plozasiran—bring the total number of approved oligonucleotide drugs to 24 across 16 clinical indications since 1998. Fitusiran and donidalorsen are the first oligonucleotide therapies approved for antithrombin deficiency and hereditary angioedema, respectively, while plozasiran represents the second approved therapy for familial chylomicronemia syndrome. All three agents employ GalNAc-mediated hepatocyte targeting, highlighting the continued importance of liver-directed delivery platforms in oligonucleotide drug development and underscoring the growing clinical maturity of this therapeutic class. Peptide-based therapeutics continue to emerge as pioneering treatments for longstanding diseases. In 2025, elamipretide further expanded this paradigm by becoming the first disease-specific treatment approved for Barth syndrome. This review provides an overview of TIDES approved in 2025, with emphasis on their chemical structures, medical targets, modes of action, routes of administration, and associated adverse effects.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Chemical Engineering, Imperial College London, London SW7 2AZ, UK.
- School of Pharmacy, Newcastle University, Newcastle upon Tyne NE1 7RU, UK.
- Orthogonal Peptides Limited, London SW7 2AZ, UK.
- School of Chemistry and Physics, University of KwaZulu-Natal, Durban 4001, South Africa.
- Department of Inorganic and Organic Chemistry, University of Barcelona, 08028 Barcelona, Spain.
- School of Laboratory Medicine and Medical Sciences, College of Health Sciences, University of KwaZulu-Natal, Durban 4001, South Africa.
ORCID-Profile: Danah AlShaer, Othman Al Musaimi, Fernando Albericio, Beatriz G de la Torre
Förderung
- National Research Foundation (NRF) South Africa
Zitieren
APA
AlShaer, D., Al Musaimi, O., Albericio, F., & de la Torre, B. G. (2026). 2025 FDA TIDES (Peptides and Oligonucleotides) Harvest. Pharmaceuticals, 19(2), 244. https://doi.org/10.3390/ph19020244
Vancouver
AlShaer D, Al Musaimi O, Albericio F, de la Torre BG. 2025 FDA TIDES (Peptides and Oligonucleotides) Harvest. Pharmaceuticals. 2026;19(2):244. doi:10.3390/ph19020244
BibTeX
@article{AlShaer2026,
author = {AlShaer, Danah and Al Musaimi, Othman and Albericio, Fernando and de la Torre, Beatriz G},
title = {2025 FDA TIDES (Peptides and Oligonucleotides) Harvest},
journal = {Pharmaceuticals},
year = {2026},
volume = {19},
number = {2},
pages = {244},
doi = {10.3390/ph19020244}
}
EUVIMED